<ul><li><div><b>Rifampin</b> is a(n)&nbsp;<u>`{{c1::inducer}}`</u> of <b>CYP-450</b></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-398766238597487.jpg" /></div></li></ul></li><li><div><b>Isoniazid</b> is a(n)&nbsp;<u>`{{c1::inhibitor}}`</u> of <b>CYP-450</b></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-398766238597487.jpg" /></div></li></ul></li><li><div>The <u>two phases of tuberculosis</u> treatment include `{{c1::4}}` drugs for `{{c1::2}}` months followed by `{{c1::2 (isoniazid and rifampin)}}` drugs for `{{c1::4}}` months</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-54704998449619.jpg" /></div></li></ul></li><li><div><u>`{{c1::Isoniazid</u> (INH)<u>}}`</u> can be used <i>alone</i> as treatment for <b>`{{c2::latent}}` tuberculosis</b> infections</div><ul><li><div><font color="#fc5a8d">Iso</font>niazid can be <font color="#fc5a8d">iso</font>lated as treatment<img src="/Users/michaelroth/AnkingImages/paste-54979876356566.jpg" /></div></li></ul></li><li><div><b>`{{c2::Isoniazid (INH)}}`</b> works by inhibiting the synthesis of `{{c1::<b>mycolic acid</b>}}` production on <i>`{{c1::Mycobacteria tuberculosis}}`</i></div><ul><li><div><i>found in the cell wall</i><i><img src="/Users/michaelroth/AnkingImages/paste-56285546414545.jpg" /></i></div></li></ul></li><li><div><b>Isoniazid (INH)</b> is a prodrug that is activated by `{{c1::KatG (a catalase-peroxidase)}}`, which is produced by <i>Mycobacteria tuberculosis</i></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-56951266345418.jpg"></div></li></ul></li><li><div>Mutations in <i>Mycobacterium tuberculosis</i> that `{{c2::down}}`-regulate the expression of <u>KatG (a catalase-peroxidase)</u> lead to <b>`{{c1::Isoniazid::drug}}` resistance&nbsp;</b></div><ul><li><div><i>Isoniazid is activated by KatG, an enzyme produced by TB</i><br><img src="/Users/michaelroth/AnkingImages/paste-57101590200787.jpg"><br></div></li></ul></li><li><div>`{{c1::<b>Peripheral neuropathy</b>}}`, <b>ataxia</b>, and <b>paresthesias</b> are common side-effects of <b>`{{c2::Isoniazid}}`</b> therapy for <i>Mycobacterium tuberculosis</i></div><ul><li><div><i>Isoniazid leads to <font color="#fc5a8d">B<sub>6</sub> deficiency</font> -&gt; results in peripheral neuropathy</i><i><br></i><i><font color="#fc5a8d">INH</font> - <font color="#fc5a8d">i</font>njury to <font color="#fc5a8d">n</font>erves and <font color="#fc5a8d">h</font>epatocytes</i><i><br></i><i><img src="/Users/michaelroth/AnkingImages/paste-57281978827215.jpg"></i></div></li></ul></li><li><div><b>Isoniazid</b> is metabolized by the <u>hepatic enzyme</u> `{{c1::N-acetyltransferase}}`</div><ul><li><div><b>n-acetyltransferase 2 (NAT2)</b><img src="/Users/michaelroth/AnkingImages/paste-58914066399689.jpg"></div></li></ul></li><li><div>Slow-`{{c1::acetylators}}` have an increased risk of <u>side effects</u> from <b>Isoniazid (INH)</b></div><ul><li><div><i>will therefore have higher drug concentrations in blood, longer drug half-lives</i><i><br /></i><i>increased risk of <font color="#fc5a8d">peripheral neuropathy</font>!!</i><i><img src="/Users/michaelroth/AnkingImages/paste-58914066399689.jpg" /></i></div></li></ul></li><li><div><b>Isoniazid</b> promotes the excretion of `{{c1::pyridoxine (Vitamin B<sub>6</sub>)}}`, therefore resulting in <i>deficiency</i> and <u>peripheral neuropathy</u></div><ul><li><div><i>**coadministration of INH with B<sub>6</sub> can prevent peripheral neuropathy</i><i><img src="/Users/michaelroth/AnkingImages/paste-60056527700429.jpg" /></i></div></li></ul></li><li><div><b>Isoniazid</b> may also cause <u>altered mental status</u> and `{{c1::<u>seizures</u>}}` (CNS toxicity)</div><ul><li><div><img src="/Users/michaelroth/AnkingImages/paste-60898341290446.jpg" />**peripheral neuropathy is a PNS toxicity</div></li></ul></li><li><div><u>`{{c1::Hepato}}`-toxicity</u> is associated with <span style="font-weight: bold">Isoniazid</span> use</div><ul><li><div><i>recall that INH is hepatically metabolized (n-acetyltransferase)</i><i><br /></i><i>INH - injury to nerves and hepatocytes</i><i><br /></i><i><img src="/Users/michaelroth/AnkingImages/paste-61602715926989.jpg" /></i></div></li></ul></li><li><div><u>Isoniazid hepatotoxicity</u> results in an<i> asymptomatic</i> rise in `{{c1::aminotransferases (AST, ALT)}}` on LFTs</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-61795989455314.jpg" /></div></li></ul></li><li><div><u>Drug-induced `{{c1::lupus}}`</u> is an <i>immunologic</i> toxicity of <b>Isoniazid</b> use</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-61950608277975.jpg" /></div></li></ul></li><li><div><b>Isoniazid</b> use can result in <u>metabolic `{{c1::acidosis::acidosis or alkalosis}}`</u>&nbsp;</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-62053687493070.jpg" /></div></li></ul></li><li><div>The <b>metabolic acidosis</b> associated with <b>Isoniazid</b> use has a(n) <u>`{{c1::elevated::normal or elevated}}` anion gap</u>&nbsp;</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-62049392525774.jpg" /></div></li></ul></li><li><div><b>Isoniazid</b> `{{c1::inhibits::induces or inhibits}}` <u>cytochrome p450</u>&nbsp;</div><ul><li><div><i>can therefore <u>increase</u> concentration of drugs such as anti-epileptics and warfarin that use CYP450 for metabolism</i><i><img src="/Users/michaelroth/AnkingImages/paste-62328565400014.jpg" /></i></div></li></ul></li><li><div><b>Rifampin</b> `{{c1::induces::induces or inhibits}}` <u>cytochrome p450</u>&nbsp;</div><ul><li><div><i>can therefore <u>decrease</u> concentration of drugs such as anti-epileptics and warfarin that use CYP450 for metabolism</i><i><br /></i><i><font color="#fc5a8d">R</font>ifampin <font color="#fc5a8d">R</font>evs up CYP450</i><i><img src="/Users/michaelroth/AnkingImages/paste-63067299774926.jpg" /></i><i></i></div></li></ul></li><li><div><b>`{{c2::Rifampin::Antibacterial}}`</b> works by binding to bacterial <u>`{{c1::DNA-dependent RNA polymerase}}`</u>, <i>inhibiting</i> <b>RNA</b> synthesis</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-63230508532180.jpg" /></div></li></ul></li><li><div><b>Mutations</b> in which <u>bacterial enzyme</u>&nbsp;can result in resistance to <b>Rifampin</b>?<br>`{{c1::DNA-dependent RNA polymerase}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-63230508532180.jpg" /></div></li></ul></li><li><div><b>Rifampin</b> is used as prophylactic <u>mono</u>-therapy in those exposed to `{{c1::<i>H. influenzae</i> and <i>Neisseria meningitidis</i>::what two bugs?}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-64463164146124.jpg"><img src="/Users/michaelroth/AnkingImages/paste-64501818851792.jpg"><img src="/Users/michaelroth/AnkingImages/paste-64342905061839.jpg"><br></div></li></ul></li><li><div><b>Rifampin</b> use is associated with <u>`{{c1::hepato}}`-toxicity</u></div><ul><li><div><i>especially when used with other hepatotoxic drugs (RIPE therapy)</i><i><br /></i><i><img src="/Users/michaelroth/AnkingImages/paste-61602715926989.jpg" /></i></div></li></ul></li><li><div>Which <u>antibacterial</u> drug may produce a <b>red-orange</b> discoloration of body fluids?<br />`{{c1::Rifampin}}`</div><ul><li><div>urine, blood, feces, spinal fluid, tears - *not dangerous!<br><img src="/Users/michaelroth/AnkingImages/paste-65279207932370.jpg"><img src="/Users/michaelroth/AnkingImages/paste-173ddf1bd1354ba006bcfa4de2974b161815bc31.jpg"><br></div></li></ul></li><li><div><b>`{{c2::Ethambutol}}`</b> blocks the enzyme `{{c1::<b>arabinosyl transferase</b>}}`, inhibiting <u>carbohydrate polymerization</u> at the bacterial cell wall</div><ul><li><div><font color="#66ccff">Arabian horse</font><img src="/Users/michaelroth/AnkingImages/paste-65455301591501.jpg"></div></li></ul></li><li><div>Which of the <u>RIPE</u> drugs is <b>bacteriostatic</b>?<br />`{{c1::Ethambutol}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-65674344923601.jpg" /></div></li></ul></li><li><div>The most serious adverse effect of <b>`{{c2::ethambutol::TB drug}}`</b> use is `{{c1::<b>optic neuritis</b>}}`, characterized by <u>loss of visual acuity</u> and <u>red-green colorblindness</u></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-65751654334937.jpg" /></div></li></ul></li><li><div><b>Pyrazinamide</b> is an antibiotic <u>only used</u> to treat <i>`{{c1::Mycobacterium tuberculosis}}`</i></div><ul><li><div><i><img src="/Users/michaelroth/AnkingImages/paste-65846143615439.jpg" /></i><i>as part of the RIPE therapy</i></div></li></ul></li><li><div>Which <u>RIPE</u> drug can cause&nbsp;<b>uric acid crystal</b> formation and ultimately <u><b>gout</b></u>?<br>`{{c1::Pyrazinamide}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-65940632895952.jpg" /></div></li></ul></li><li><div><b>Pyrazinamide</b> is associated with <u>hyper-`{{c1::uricemia</u><u>}}`</u></div><ul><li><div><i>and therefore gout</i><i><img src="/Users/michaelroth/AnkingImages/paste-65936337928656.jpg" /></i></div></li></ul></li><li><div><b>Pyrazinamide</b> is `{{c1::hepato}}`-toxic, even leading to `{{c1::liver}}` necrosis</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-61602715926989.jpg" /></div></li></ul></li><li><div><b>Pyrazinamide</b> is a pro-drug that is converted into the active form, `{{c1::pyrazinoic acid}}`, by the enzyme <b>pyrazinamidase</b></div><ul><li><div>thus, resistance can occur with modification of pyrazinamidase</div></li></ul></li><li><div>`{{c1::<b>Pyrazinamide</b>}}` readily crosses the <u>blood-brain barrier</u>, and is used to treat <b>tuberculous meningitis</b></div><ul><li></li></ul></li><li><div>The <b>B<sub>6</sub> depletion</b> with <u>Isoniazid</u> use can lead to <i>decreased</i> `{{c1::protoporphyrin}}` <b>synthesis</b>, leading to a(n)&nbsp;<u>`{{c1::sideroblastic}}` anemia</u></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-333839217983923.jpg" /></div></li></ul></li><li><div><font color="#fc5a8d">Rifampin</font> can be remembered by the 4 R's<br>DNA-dependent <font color="#fc0280">R</font>NA polymerase inhibitor<br><font color="#fc0280">R</font>amps up microsomal CYP450<br><font color="#fc0280">R</font>ed/orange body fluids<br>Rapid `{{c4::<font color="#fc5a8d">R</font>esistance}}` if used alone</div><ul><li></li></ul></li><li><div><i>Mycobacterium `{{c1::avium complex</i><i>}}`</i> is a non-TB disease that causes <u>disseminated infection</u> in the late stages of <b>`{{c2::AIDS}}`</b></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-86870008529263.jpg" /></div></li></ul></li><li><div><i>Mycobacterium avium complex</i> includes <i>`{{c1::Mycobacterium avium}}` and </i><i>`{{c1::Mycobacterium intracellulare</i>}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-85998130168180.jpg" /></div></li></ul></li><li><div><i>Mycobacterium avium complex</i> is treated with `{{c1::<u>azithromycin/clarithromycin</u> (a macrolide)}}` combined with `{{c2::<u>ethambutol</u>}}`</div><ul><li><div><i>***can also add <font color="#fc5a8d">rifabutin</font></i><img src="/Users/michaelroth/AnkingImages/paste-21272973017494.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-86088324481393.jpg" /></div></li></ul></li><li><div>`{{c2::<b>Azithromycin</b>}}` prophylaxis for <i>Mycobacterium avium complex </i>should be started with <u>CD4+ counts</u> `{{c1::<b>&lt; 50</b>}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-86990267613555.jpg" /><img src="/Users/michaelroth/AnkingImages/Xnip2018-03-89_13-48-54.jpg" /></div></li></ul></li><li><div>`{{c1::Rifabutin}}` may be added as a <u>third agent</u> in the treatment of <i>Mycobacterium avium complex</i></div><ul><li><div><i>***along with macrolides (azithromycin/clarithromycin) and ethambutol</i><i><img src="/Users/michaelroth/AnkingImages/paste-87677462380915.jpg" /></i></div></li></ul></li><li><div><b>Rifabutin</b> `{{c1::induces::induces or inhibits}}` <u>cytochrome p450</u>&nbsp;</div><ul><li><div><i>**less potent CYP450 activator when compared to rifampin</i><i>can therefore <u>decrease</u> concentration of drugs such as anti-epileptics and warfarin that use CYP450 for metabolism</i><img src="/Users/michaelroth/AnkingImages/paste-88334592377201.jpg" /></div></li></ul></li><li><div>Because <b>`{{c1::Rifabutin}}`</b> induces CYP450 <i>less</i> than other drugs in its class (i.e.&nbsp;Rifampin), it is used in the treatment of <u>`{{c2::tuberculosis}}`</u> in <b>`{{c2::HIV}}`</b> patients</div><ul><li><div>HIV drugs NRTIs are metabolized by CYP450, therefore the less aggressive induction of CYP450 doesn't counteract the dosing of NRTIs<br></div></li></ul></li><li><div>Side-effects of <u>Dapsone</u> include `{{c1::<b>agranulocytosis</b>}}` and `{{c2::<b>hemolytic anemia in G6PD deficiency</b>}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-89481348645231.jpg"><img src="/Users/michaelroth/AnkingImages/paste-90310277333396.jpg"><img src="/Users/michaelroth/AnkingImages/paste-22604412879247.jpg"></div></li></ul></li><li><div>What drug used to treat <i>Mycobacteria leprae&nbsp;</i>may present with <u>Heinz bodies</u> and <b>bite cells (degmacytes)</b>?<br>`{{c1::Dapsone}}`</div><ul><li><div><i>due to it causing hemolytic anemia in G6PD deficiency</i><i><br /></i><i><img src="/Users/michaelroth/AnkingImages/paste-89751931584880.jpg" /></i></div></li></ul></li><li><div><i>Mycobacteria `{{c1::marinum}}`</i> causes a <u>hand-infection</u> in <b>aquarium handlers</b></div><ul><li></li></ul></li><li><div><i>Mycobacteria `{{c1::scrofulaceum}}`</i> causes <b>cervical lymphadenitis</b> in <u>children</u></div><ul><li></li></ul></li><li><div>What drug can be used <i>instead</i> of <b>Ethambutol&nbsp;</b>to treat <i>Mycobacteria tuberculosis</i> infection?<br>`{{c1::Streptomycin}}`</div><ul><li></li></ul></li><li><div>Which etiology of <u>meningitis</u> is <b>Pyrazinamide</b> prescribed to treat?<br /><i>`{{c1::M. tuberculosis}}`</i></div><ul><li><div>readily crosses the blood-brain barrier</div></li></ul></li><li><div>Which <u>RIPE therapy</u> drug can cause <b>drug-induced lupus</b>?<br>`{{c1::Isoniazid}}`<br></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-61950608277975.jpg" /></div></li></ul></li><li><div><b>Rifampin</b> is a <b>CYP450</b> <u>`{{c1::activator}}`</u> and thus is contraindicated in HIV due to it <u>`{{c1::decreasing}}`</u> HIV `{{c2::<b>protease</b>}}`<b> inhibitor</b> serum concentrations</div><ul><li><div><i>instead, rifabutin is used (weaker inducer of cyp450)</i><img src="/Users/michaelroth/AnkingImages/paste-41510858916229.jpg" /></div></li></ul></li><li><div>What drug is used <u>instead of Rifampin</u> in patients on <b>HIV protease inhibitors</b>?<br>`{{c1::Rifabutin}}`</div><ul><li><div><i>weaker inducer of CYP450, thus does not affect serum concentration of protease inhibitors as much</i><img src="/Users/michaelroth/AnkingImages/paste-41510858916229.jpg" /></div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [F]</b></font>) of Bacterial Genetics do <b>Rifamycins</b> impact?<br /><b>`{{c1::<font color="#aa0000">[D]</font>}}`</b><br /><img src="paste-573073191337985.jpg" /></div><ul><li><div>Rifamycins (<b>Rifampin </b>&amp; <b>Rifabutin</b>) Inhibits DNA-<b>dependent</b> RNA polymerase<br><img src="/Users/michaelroth/AnkingImages/paste-718749892083713.jpg"><br><img src="/Users/michaelroth/AnkingImages/paste-313128885682177.jpg"></div></li></ul></li><li><div>Which one of the following drugs is a <i>major</i>&nbsp;<u>cytochrome p450</u> <b>inducer?</b><br><br><b>`{{c1::Rifampin}}`</b><b><br></b><img src="paste-718749892083713.jpg"></div><ul><li><div>- Rifampin also induces <b>UDP-Glucuronyltransferase </b>(Phase II Metabolism)<b><br /></b>- Thus use <b>Rifabutin</b> (does not stimulate / inhibit cyp450) in patients with <u>HIV infection</u> (ex when treating a MAC infection) as certain HIV drugs are metabolized by cyp450 (ex. <b>Protease inhibitors</b>)<br /><img src="/Users/michaelroth/AnkingImages/paste-720330440048641.jpg" /><br /><img src="/Users/michaelroth/AnkingImages/paste-285207303290881.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-122917669044225.jpg" /></div></li></ul></li><li><div>Is <b>Rifampin/Rifabutin</b> indicated to treat both tuberculous and nontuberculous mycobacteria?<br />`{{c1::Yes}}`</div><ul><li><div>- Tuberculous (<b><font color="#aa0000">R</font></b>IPE)- Tuberculoid Leprosy- MAC treatment adjunct<br /><img src="/Users/michaelroth/AnkingImages/paste-305994945003521.jpg" /></div></li></ul></li><li><div><b>Rifampin</b> is used for close-contact prophylaxis of the following non-<u>mycobacterial</u> species<br />1 - `{{c1::Neisseria Meningitidis}}`2 - `{{c2::Haemophilus Influenzae B}}`</div><ul><li><div>- Hib close contact prophylaxis in KIDS<br /><img src="/Users/michaelroth/AnkingImages/paste-320237056557057.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-326812651487233.jpg" /></div></li></ul></li><li><div>Use of <b>Rifamycins</b> can change the color of bodily fluids to `{{c1::Red / Orange}}`</div><ul><li><div>This is a non-hazardous side effect<br /><img src="/Users/michaelroth/AnkingImages/paste-333925117329409.jpg" /></div></li></ul></li><li><div><b>Rifamycins</b> can cause minor `{{c1::hepato}}`toxicity</div><ul><li><div>Remember, Rifabutin does NOT stimulate cyp450, while Rifampin DOES stimulate cyp450<br /><img src="/Users/michaelroth/AnkingImages/paste-365901148848129.jpg" /></div></li></ul></li><li><div>Resistance to <b>Rifamycins</b> is developed when mutations reduce binding to `{{c1::RNA polymerase}}`</div><ul><li><div>Resistance <b>rapidly</b> develops if Rifamycins are <u>given alone</u> <br /><img src="/Users/michaelroth/AnkingImages/paste-313128885682177.jpg" /></div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [D]</b></font>) of Mycobacterial homeostasis does <b>Isoniazid (INH)</b> impact?<br /><span style="color: rgb(170, 0, 0)"><b>`{{c1::[C]}}`</b></span><span style="color: rgb(170, 0, 0);"><b><br /></b></span><img src="paste-737321330671617.jpg" /></div><ul><li><div>The <b>active <u>metabolite</u></b> of isoniazid decreases synthesis of mycolic acid <br /><img src="/Users/michaelroth/AnkingImages/paste-224652559384577.jpg" /><br /></div></li></ul></li><li><div><b>Isoniazid</b> must be converted by a mycobacterial `{{c1::catalase-peroxidase}}` to its active metabolite</div><ul><li><div>This enzyme is encoded by the gene <b>KatG</b><b><br /></b><b><img src="/Users/michaelroth/AnkingImages/paste-217497143869441.jpg" /></b></div></li></ul></li><li><div>People who have <u>decreased</u> levels of the liver enzyme `{{c1::<b>n-acetyltransferase 2 (NAT2)</b>}}` lead to an increased risk** of <u>toxicity</u></div><ul><li><div>- NAT2 is the main metabolic enzyme for INH<br />- People who have decreased levels of NAT2 are deemed "slow" acetylators, and those who have normal are deemed "fast" acetylators<br /><img src="/Users/michaelroth/AnkingImages/paste-255133942284289.jpg" />z<br />- **Recent literature has shown this to have an pathologic effect (as seen via research articles and reviews from 2017 to 2016), but this is still controversial (Boards and Beyond)</div></li></ul></li><li><div><b>Isoniazid</b> can cause `{{c1::hepato}}`toxicity</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-792825193037825.jpg" /><br /><img src="/Users/michaelroth/AnkingImages/paste-239796614070273.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-365896853880833.jpg" /></div></li></ul></li><li><div>If a patient on <b>Isoniazid</b> develops <u>arthralgias</u> and a <u>rash</u>, you should suspect the patient has developed `{{c1::Drug Induced Lupus}}`</div><ul><li><div>- removal of INH will stop lupus- Key serological finding is that the patient will develop <b>anti-histone antibodies</b><b><br /></b><b><img src="/Users/michaelroth/AnkingImages/paste-263307265048577.jpg" /></b></div></li></ul></li><li><div><b>Isoniazid</b> is a cytochrome p450 `{{c1::inhibitor}}`</div><ul><li><div>Extra <br><i></i><i><img src="/Users/michaelroth/AnkingImages/paste-278039002873857.jpg"><br></i>Remember the mnemonic<font color="#aa0000"><b>:</b></font><i><br></i><i><img src="/Users/michaelroth/AnkingImages/paste-181900454920193.jpg"></i></div></li></ul></li><li><div>Patients that <u>overdose</u> on <b>Isoniazid</b> will develop `{{c1::seizures}}`</div><ul><li><div>Via decrease in availability of GABA<br /><br /><img src="/Users/michaelroth/AnkingImages/paste-298800874782721.jpg" /></div></li></ul></li><li><div>Patients that <u>overdose</u> on <b>Isoniazid</b> can develop a(n) `{{c1::high}}` anion gap metabolic acidosis </div><ul><li><div>This is because INH induced <u>seizures</u> lead to <b>lactic acidosis</b><b><br /></b><b><img src="/Users/michaelroth/AnkingImages/paste-382535557185537.jpg" /></b><b><img src="/Users/michaelroth/AnkingImages/paste-298796579815425.jpg" /></b></div></li></ul></li><li><div>If a patient on <b>Isoniazid</b> develops peripheral neuropathy and fatigue, you should suspect they have developed what vitamin deficiency?<br />`{{c1::Vitamin B6}}`</div><ul><li><div>INH is similar to B6 structure, thus it can bind and inhibit pyridoxine phosphokinase (which makes active B6 - pyridoxal phosphate (PLP); thus <b>supplement vitamin B6 </b><br />- patients are fatigued due to developing a <b>sideroblastic anemia</b> (ringed sideroblasts under prussian blue staining in bone marrow; basophillic stippling in periphery)<br />(<i>Sketchy Mechanism is INCORRECT based on B&amp;B and UpToDate)</i><img src="/Users/michaelroth/AnkingImages/paste-270402551021569.jpg" /><br /></div></li></ul></li><li><div>Resistance to <b>Isoniazid </b>can develop due to mutations that lead to <b>under</b>expression of `{{c1::<b>KatG</b>}}`</div><ul><li><div>KatG encodes the mycobacterial catalase-peroxidase that activates INH <br><img src="/Users/michaelroth/AnkingImages/paste-246973504421889.jpg"><img src="/Users/michaelroth/AnkingImages/paste-217501438836737.jpg"></div></li></ul></li><li><div>Is <b>Isoniazid</b> indicated to treat both tuberculous and nontuberculous mycobacteria?<br />`{{c1::No}}`</div><ul><li><div>Only Mycobacterium Tuberculosis<br /><img src="/Users/michaelroth/AnkingImages/paste-210221469270017.jpg" /></div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [D]</b></font>) of Mycobacterial homeostasis does <b>Ethambutol</b> impact?<br /><span style="color: rgb(170, 0, 0)"><b>`{{c1::[D]}}`</b></span><span style="color: rgb(170, 0, 0); "><b><br /></b></span><img src="paste-737321330671617.jpg" /><br /></div><ul><li><div>Inhibits mycobacterial arabinosyl transferases which are part of the polymerization reaction of <b>arabinogalactan</b> (important part of the mycobacterial cell wall)<br /><img src="/Users/michaelroth/AnkingImages/paste-389648023027713.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-375350076899329.jpg" /></div></li></ul></li><li><div>Patients taking <b>Ethambutol</b> can manifest with `{{c1::red-green}}` color blindness</div><ul><li><div>This is due to ethambutol damaging the <b>retinal ganglion cells</b> via excitotoxic pathways<br />- This manifests early as blue-yellow color blindness early (which typical color blindness screens don't pick up), then <u>develops into a red-green color blindness</u><u><br /></u>- Eventually, patients can develop a central scotoma<br /><img src="/Users/michaelroth/AnkingImages/paste-805572655972353.jpg" /><br /><img src="/Users/michaelroth/AnkingImages/paste-397108381220865.jpg" /></div></li></ul></li><li><div>Is <b>Ethambutol</b> indicated to treat both tuberculous and nontuberculous mycobacteria?<br />`{{c1::Yes}}`</div><ul><li><div>- Tuberculosis- MAC infections (Ethambutol + Macrolide)</div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [D]</b></font>) of Mycobacterial homeostasis does <b>Pyrazinamide</b> impact?<br /><span style="color: rgb(170, 0, 0)"><b>`{{c1::[B]}}`</b></span><span style="color: rgb(170, 0, 0); "><b><br /></b></span><img src="paste-737321330671617.jpg" /><br /></div><ul><li><div>- Unclear mechanism, but the active form disrupts mycobacterial cell metabolism and transport functions<br /><img src="/Users/michaelroth/AnkingImages/paste-341389770489857.jpg" /></div></li></ul></li><li><div><b>Pyrazinamide</b> is activated to its active metabolite `{{c1::<b>pyrazinoic acid</b>}}` in the host `{{c2::<u>phagolysosome</u>}}`</div><ul><li><div>This conversion works best at <u>acidic pH</u><br />Pyrazinoic acid <b>inhibits a bifunctional enzyme</b> that is involved in:- metabolism of RNA / ssDNA - metabolism of Guanosine pentaphosphate, which is involved in bacterial response to highly stressful conditions ("Stringent Response")</div></li></ul></li><li><div><b>Streptomycin</b> is a <u>second line</u> anti-tuberculosis drug that is a(n) `{{c1::aminoglycoside}}`</div><ul><li><div>Irreversibly binds the 30S ribosomal subunit and prevents formation of the <u>Initiation Complex</u><br><img src="/Users/michaelroth/AnkingImages/paste-815163317944321.jpg" class="resizer"><br><img src="/Users/michaelroth/AnkingImages/paste-404246616866817.jpg" class="resizer"></div></li></ul></li><li><div><b>Streptomycin</b> has notable `{{c1::CNS}}` toxicity and nephrotoxicity</div><ul><li><div>Can cause tinnitus, vertigo, ataxia</div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [F]</b></font>) of Bacterial Genetics does <b>Dapsone</b> impact?<br><b>`{{c1::<font color="#aa0000">[A]</font>}}`</b><br><img src="paste-573073191337985.jpg" style="width: 800px;"></div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-816636491726849.jpg" draggable="false"></div></li></ul></li><li><div><b>Dapsone</b> is used to treat Mycobacterium `{{c1::<b>leprae</b>}}`</div><ul><li></li></ul></li><li><div>Which form of <u>Leprosy</u> is <b>Dapsone</b> used to treat? Lepromatous or Tuberculoid?<br />`{{c1::Both :)}}`</div><ul><li><div>Given with rifampin for tuberculoid form, clofazimine is added to the regimen for lepromatous form</div></li></ul></li><li><div><b>Rifampin</b> is given with <u>Dapsone</u> because it `{{c1::delays resistance}}` to <u>Dapsone</u></div><ul><li></li></ul></li><li><div><b>Dapsone</b> can be used to treat the <i>blistering</i> skin disorder `{{c1::Dermatitis Herpetiformis}}`</div><ul><li><div>- Inhibits <b>Myeloperoxidase</b>, preventing accumulation of HOCl<sup>- </sup>and reduces tissue damage during inflammation<br />- For this reason, some also use for necrotic brown recluse bites, but clinical evidence is lacking</div></li></ul></li><li><div><b>Dapsone</b> can be used for <u>prophylaxis</u> of `{{c1::Pneumocystis Jirovecii}}`</div><ul><li><div>- Use in cases where there is an allergy to TMP-SMX (although since Dapsone is a sulfa drug patient also may be allergic)</div></li></ul></li><li><div>Which step (<font color="#aa0000"><b>[A] - [F]</b></font>) of Bacterial Genetics does <b>Clofazimine</b> impact?<br><b>`{{c1::<font color="#aa0000">[F]</font>}}`</b><br><img src="paste-573073191337985.jpg"></div><ul><li><div>- Binds to <b>guanines</b> in bacterial DNA, p<u>reventing template function</u> of DNA (This inhibits bacterial proliferation)- Additionally, activates <b>PLA2</b>, which results in an accumulation of toxic lysophospholipids</div></li></ul></li><li><div><b>Clofazimine</b> is used to treat Mycobacterium `{{c1::<b>leprae</b>}}`</div><ul><li></li></ul></li><li><div>Which form of <u>Leprosy</u> is <b>Clofazimine</b>&nbsp;used to treat? Lepromatous or Tuberculoid?<br>`{{c1::Lepromatous)}}`</div><ul><li><div>Clofazimine is added to Dapsone + Rifampin to treat lepromatous leprosy</div></li></ul></li><li><div>What is the recommended&nbsp;<b>primary prophylaxis</b>&nbsp;against&nbsp;<i>mycobacterium avium complex (MAC)&nbsp;</i>for&nbsp;<u>HIV patients</u>&nbsp;with <b>CD4 count &lt;50/mm</b>?<br><br>`{{c1::<b>None :)</b>}}`</div><ul><li><div>This card previously said that primary prophylaxis for MAC is recommended, however, UWorld confirms that we&nbsp;<u style="font-weight: bold;">no longer</u>&nbsp;give prophylactic treatments for MAC<br><br><img src="/Users/michaelroth/AnkingImages/paste-452638013390849.jpg"></div></li></ul></li><li><div><b>Pyrazinamide</b> is associated with side effects of <u>hepatotoxicity</u> and <u>hyper</u>`{{c1::<u>uric</u>}}`<u>emia</u></div><ul><li><div>- Organic ions (ex Pyrazinoate - metabolite of Pyrazinamide) counter-ion for uric acid at the URAT1 antiporter on the apical surface of the collecting duct<br />- thus the more Pyrazinamide secreted into the urine, more uric acid reabsorbed into the blood (same mechanism for Niacin ingestion and Lactate)<br /><img src="/Users/michaelroth/AnkingImages/paste-46312632352769.jpg" /><br /><br /><img src="/Users/michaelroth/AnkingImages/paste-348562365874177.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-358853107515393.jpg" /><img src="/Users/michaelroth/AnkingImages/paste-365896853880833.jpg" /></div></li></ul></li><li><div>When treating patients with <i>M avium-intracellulare (MAC) </i>infections, you can give <b>`{{c1::Ethambutol}}` </b>+ <b>`{{c1::Macrolides*}}`</b></div><ul><li><div>- *Azithromycin or Clarithromycin- <u>Rifabutin</u> or <u>Ciprofloxacin</u> can be added as needed<br /><img src="/Users/michaelroth/AnkingImages/paste-452633718423553.jpg" /></div></li></ul></li><li><div><b>Streptomycin</b> can be also used to treat what zoonotic infection?<br />`{{c1::<b>Tularemia</b>}}`</div><ul><li><div>Extra <br><img src="/Users/michaelroth/AnkingImages/paste-367404387401729.jpg" /></div></li></ul></li><li><div>Treatment of tuberculosis with <b>isoniazid</b> can result in mycobacteria losing their "`{{c1::acid-fastness}}`", which will be visible on culture</div><ul><li><div>loss of mycolic acid synthesis prevents retention of acid fast dye</div></li></ul></li><li><div>Isoniazid works to treat tuberculosis by inhibiting mycobacterial `{{c1::cell wall}}` production</div><ul><li><div>without mycolic acid, the mycobacterium lose their acid-fastness and become unable to synthesize new cell walls and multiply</div></li></ul></li><li><div>Should you ever treat <b>active </b>tuberculosis with a monotherapy?<br />`{{c1::NO!}}`</div><ul><li><div>- Resistance develops rapidly due to "selective" gene mutations (Tb with gene mutations will survive, so monotherapy selects for those resistant types)<br />- thus treatment of active Tb is accomplished by combining multiple antibiotics to avoid selecting for resistant strains</div></li></ul></li><li><div><b>Isoniazid</b> can be given as a monotherapy for tuberculosis ONLY when there is a(n) `{{c1::positive}}` PPD and a(n) `{{c1::negative}}` chest x-ray</div><ul><li><div>aka these patients have NO evidence of clinical disease</div></li></ul></li></ul>